Under national health screening guidelines, adults undergo routine dyslipidemia blood panels every four years—starting at age 24 for men and age 40 for women. These standard tests evaluate total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. However, a major independent risk factor for cardiovascular disease is entirely absent from this standard panel: lipoprotein(a), commonly known as Lp(a).
In recent years, cardiologists worldwide have increasingly advocated for routine Lp(a) screening to evaluate cardiovascular risk more accurately. Both the American Heart Association (AHA) and the American College of Cardiology (ACC) recommend that all adults have their Lp(a) levels measured at least once in their lifetime. Structurally, Lp(a) consists of an apolipoprotein(a) molecule bound to a particle similar to low-density lipoprotein (LDL), or "bad cholesterol." Because circulating Lp(a) levels are overwhelmingly determined by genetics, they fluctuate very little in response to diet or exercise. Consequently, a single lifetime test is generally sufficient for most adults.
How Lp(a) Drives Cardiovascular Risk
Testing is particularly critical for individuals with early-onset cardiovascular disease, a personal or family history of heart conditions, familial hypercholesterolemia (FH), or a known family history of elevated Lp(a).
Once in the bloodstream, Lp(a) penetrates the inner lining of arterial walls, delivering cholesterol while carrying oxidized phospholipids (OxPL) that spark localized inflammation. This dual action accelerates the formation and progression of atherosclerotic plaque. As plaque accumulates, it narrows blood vessels and restricts blood flow; if a plaque ruptures, it can trigger a blood clot, potentially resulting in a heart attack or stroke.
Managing Risk When Lp(a) Is Elevated
Dr. Jeffrey Berger, director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart Center, noted in an interview with The Washington Post that because high Lp(a) increases cardiovascular risk, identifying genetic predisposition early allows patients to manage modifiable risk factors like lifestyle and cholesterol more aggressively.
Currently, there are no established, widely approved therapies specifically designed to meaningfully lower Lp(a) levels. As a result, Dr. Berger stresses that individuals with high Lp(a) must meticulously manage overall cardiovascular risk factors, particularly blood sugar, blood pressure, and LDL cholesterol.
Lowering LDL cholesterol requires a comprehensive approach. The AHA emphasizes replacing saturated fats—found in cuts like pork belly, processed meats, butter, and heavy cream—with unsaturated fats, while prioritizing fiber-rich foods such as fish, beans, nuts, vegetables, fruit, legumes, and whole grains. Beyond diet, guidelines recommend at least 150 minutes of moderate-intensity physical activity per week, maintaining a healthy weight, limiting alcohol intake, and completely avoiding smoking.
However, if LDL cholesterol remains persistently high or if additional risk factors like elevated Lp(a) are present, lifestyle modifications alone may not suffice. In such cases, patients should consult medical professionals to explore appropriate pharmacological treatments.
